154 related articles for article (PubMed ID: 35818588)
41. In silico studies on p21-activated kinase 4 inhibitors: comprehensive application of 3D-QSAR analysis, molecular docking, molecular dynamics simulations, and MM-GBSA calculation.
Gao Y; Wang H; Wang J; Cheng M
J Biomol Struct Dyn; 2020 Sep; 38(14):4119-4133. PubMed ID: 31556340
[TBL] [Abstract][Full Text] [Related]
42. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of the anti-diabetic drug sitagliptin as a novel attenuate to SARS-CoV-2 evidence-based in silico: molecular docking and molecular dynamics.
da Cruz Freire JE; Júnior JEM; Pinheiro DP; da Cruz Paiva Lima GE; do Amaral CL; Veras VR; Madeira MP; Freire EBL; Ozório RG; Fernandes VO; Montenegro APDR; Montenegro RC; Colares JKB; Júnior RMM
3 Biotech; 2022 Dec; 12(12):344. PubMed ID: 36382241
[TBL] [Abstract][Full Text] [Related]
44.
Shirvani P; Fassihi A
J Biomol Struct Dyn; 2022 Aug; 40(13):5965-5982. PubMed ID: 33475043
[TBL] [Abstract][Full Text] [Related]
45. Synthesis and Biological Evaluation of Quinolinone Compounds as SARS CoV 3CL
Sun Y; Zhang N; Wang J; Guo Y; Sun B; Liu W; Zhou H; Yang C
Chin J Chem; 2013 Sep; 31(9):1199-1206. PubMed ID: 32313409
[TBL] [Abstract][Full Text] [Related]
46. In Silico Exploration of Aryl Halides Analogues as Checkpoint Kinase 1 Inhibitors by Using 3D QSAR, Molecular Docking Study, and ADMET Screening.
Ghaleb A; Aouidate A; Bouachrine M; Lakhlifi T; Sbai A
Adv Pharm Bull; 2019 Feb; 9(1):84-92. PubMed ID: 31011562
[No Abstract] [Full Text] [Related]
47. Design of novel benzimidazole derivatives as potential α-amylase inhibitors using QSAR, pharmacokinetics, molecular docking, and molecular dynamics simulation studies.
Abchir O; Daoui O; Belaidi S; Ouassaf M; Qais FA; ElKhattabi S; Belaaouad S; Chtita S
J Mol Model; 2022 Mar; 28(4):106. PubMed ID: 35352175
[TBL] [Abstract][Full Text] [Related]
48. Cyclohexane-1,3-dione Derivatives as Future Therapeutic Agents for NSCLC: QSAR Modeling, In Silico ADME-Tox Properties, and Structure-Based Drug Designing Approach.
Daoui O; Elkhattabi S; Bakhouch M; Belaidi S; Bhandare RR; Shaik AB; Mali SN; Chtita S
ACS Omega; 2023 Jan; 8(4):4294-4319. PubMed ID: 36743017
[TBL] [Abstract][Full Text] [Related]
49. Design of novel dopamine D
Zhang C; Li Q; Meng L; Ren Y
J Biomol Struct Dyn; 2020 Feb; 38(3):860-885. PubMed ID: 30916624
[TBL] [Abstract][Full Text] [Related]
50. Docking-based 3D-QSAR (CoMFA, CoMFA-RG, CoMSIA) study on hydroquinoline and thiazinan-4-one derivatives as selective COX-2 inhibitors.
Dowlati Beirami A; Hajimahdi Z; Zarghi A
J Biomol Struct Dyn; 2019 Jul; 37(11):2999-3006. PubMed ID: 30035675
[TBL] [Abstract][Full Text] [Related]
51. Structural basis of SARS-CoV-2 3CL
Tahir Ul Qamar M; Alqahtani SM; Alamri MA; Chen LL
J Pharm Anal; 2020 Aug; 10(4):313-319. PubMed ID: 32296570
[TBL] [Abstract][Full Text] [Related]
52. Screening of phytochemical compounds of
Krupanidhi S; Abraham Peele K; Venkateswarulu TC; Ayyagari VS; Nazneen Bobby M; John Babu D; Venkata Narayana A; Aishwarya G
J Biomol Struct Dyn; 2021 Sep; 39(15):5799-5803. PubMed ID: 32627715
[TBL] [Abstract][Full Text] [Related]
53. In silico study to identify novel potential thiadiazole-based molecules as anti-Covid-19 candidates by hierarchical virtual screening and molecular dynamics simulations.
Rashdan HRM; Abdelmonsef AH
Struct Chem; 2022; 33(5):1727-1739. PubMed ID: 35729938
[TBL] [Abstract][Full Text] [Related]
54. Allosteric Regulation of 3CL Protease of SARS-CoV-2 and SARS-CoV Observed in the Crystal Structure Ensemble.
Kidera A; Moritsugu K; Ekimoto T; Ikeguchi M
J Mol Biol; 2021 Dec; 433(24):167324. PubMed ID: 34717972
[TBL] [Abstract][Full Text] [Related]
55. Computer aided drug design based on 3D-QSAR and molecular docking studies of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amine derivatives as PIM2 inhibitors: a proposal to chemists.
Aouidate A; Ghaleb A; Ghamali M; Chtita S; Ousaa A; Choukrad M; Sbai A; Bouachrine M; Lakhlifi T
In Silico Pharmacol; 2018; 6(1):5. PubMed ID: 30607318
[TBL] [Abstract][Full Text] [Related]
56. CoMFA, CoMSIA, Topomer CoMFA, HQSAR, molecular docking and molecular dynamics simulations study of triazine morpholino derivatives as mTOR inhibitors for the treatment of breast cancer.
Chhatbar DM; Chaube UJ; Vyas VK; Bhatt HG
Comput Biol Chem; 2019 Jun; 80():351-363. PubMed ID: 31085426
[TBL] [Abstract][Full Text] [Related]
57. Macrolactin A as a Novel Inhibitory Agent for SARS-CoV-2 M
Bharadwaj KK; Sarkar T; Ghosh A; Baishya D; Rabha B; Panda MK; Nelson BR; John AB; Sheikh HI; Dash BP; Edinur HA; Pati S
Appl Biochem Biotechnol; 2021 Oct; 193(10):3371-3394. PubMed ID: 34212286
[TBL] [Abstract][Full Text] [Related]
58. Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors.
Achutha AS; Pushpa VL; Suchitra S
J Proteome Res; 2020 Nov; 19(11):4706-4717. PubMed ID: 32960061
[TBL] [Abstract][Full Text] [Related]
59. 3D computer modeling of inhibitors targeting the MCF-7 breast cancer cell line.
Zarougui S; Er-Rajy M; Faris A; Imtara H; El Fadili M; Qurtam AA; Nasr FA; Al-Zharani M; Elhallaoui M
Front Chem; 2024; 12():1384832. PubMed ID: 38887699
[TBL] [Abstract][Full Text] [Related]
60. Discovery of new oxadiazolo pyridine derivatives as potent ghrelin O-acyltransferase inhibitors using molecular modeling techniques.
Sarkar K; Das B; Das RK
In Silico Pharmacol; 2023; 11(1):35. PubMed ID: 37954893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
